PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
ED  - Pirmohamed, Munir
TI  - EU-PACT Study: Initial Warfarin Dosing Improved by Clinical Variables and Genotype to Guide Therapy
DP  - 2013  01
TA  - MD Conference Express
PG  - 19--19
VI  - 13
IP  - 20
4099  - http://mdc.sagepub.com/content/13/20/19.short
4100  - http://mdc.sagepub.com/content/13/20/19.full
AB  - Response to warfarin is highly variable, making it difficult to select the optimal dose. Typical doses can range from 0.5 to 20 mg per day, and various factors, such as genetics, can influence an individual's daily dose. The purpose of the European Union Pharmacogenetics of Anticoagulant Therapy Warfarin Study [EU-PACT; Pirmohamed M et al. N Engl J Med 2013] was to compare whether the use of clinical variables and genotype information improves the time in therapeutic range compared with “standard” dosing.